Journal of Cardiovascular Medicine最新文献

{"title":"'Neither too young nor too old': delayed diagnosis of anomalous left coronary artery from pulmonary artery.","authors":"Anaïs Curtiaud, Mohamad Kanso, Mickael Ohana, Laurence Jesel","doi":"10.2459/JCM.0000000000001731","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001731","url":null,"abstract":"","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine for prevention of major adverse cardiovascular events: a meta-analysis of randomized clinical trials.","authors":"Federico Ballacci, Federica Giordano, Cristina Conte, Alessandro Telesca, Valentino Collini, Massimo Imazio","doi":"10.2459/JCM.0000000000001744","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001744","url":null,"abstract":"<p><strong>Aims: </strong>Inflammation is a main pathophysiological driver in atherosclerotic cardiovascular diseases (ASCVD). Low-dose long-term colchicine for secondary prevention in patients with established ASCVD has been studied in multiple randomized trials in the last decade.This meta-analysis aimed to evaluate the efficacy and safety of long-term low-dose colchicine for secondary prevention in patients with established ASCVD.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines to evaluate studies reporting long-term outcomes in patients with ASCVD. We systematically searched PubMed, EMBASE and Scopus databases for relevant studies up to 1 December 2024. The primary outcome was the occurrence of major adverse cardiovascular events (MACE), a composite of cardiovascular death (CVD), myocardial infarction (MI) and stroke. Random-effects models were used to calculate pooled risk ratios (RRs).</p><p><strong>Results: </strong>Ten randomized clinical trials enrolling 22 532 patients were identified. Addition of colchicine to standard medical treatment in patients with established ASCVD reduced the risk for MACE by 27% [RR 0.73, 95% confidence interval (CI) 0.57-0.95], with a number needed to treat of 52. Colchicine was found to significantly reduce the risk of MI (RR 0.83, 95% CI 0.72-0.96) and coronary revascularization (RR 0.79, 95% CI 0.65-0.94). There were no significant differences between the two groups concerning cardiovascular and noncardiovascular mortality, risk of serious gastrointestinal events, infections requiring hospitalization and cancer.</p><p><strong>Conclusions: </strong>These findings support the use of long-term low-dose colchicine for secondary prevention of MACE in clinical practice.</p>","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of age, estimated glomerular filtration rate and ejection fraction (AGEF) score for all-cause 90-day mortality in patients with cardiogenic shock.","authors":"Yaoji Liao, Dandong Luo, Xin Zhang, Tingting Liu, Chongjian Zhang","doi":"10.2459/JCM.0000000000001729","DOIUrl":"10.2459/JCM.0000000000001729","url":null,"abstract":"<p><strong>Aims: </strong>Age, estimated glomerular filtration rate and ejection fraction (AGEF) score correlates with mortality in patients with ST-elevation myocardial infarction, yet its relationship with cardiogenic shock mortality remains unknown.</p><p><strong>Objectives: </strong>This research aims to explore the correlation between AGEF and the probability of all-cause 90-day mortality in patients with cardiogenic shock.</p><p><strong>Methods: </strong>Our study included 168 cardiogenic shock patients from a multicenter, prospective, observational study. The Cox regression model, subgroup analyses, Kaplan-Meier survival curves, and restricted cubic spline analysis were applied to assess the relationship between AGEF and 90-day mortality. Receiver-operating characteristic curve analysis was performed to evaluate the predictive accuracy of AGEF for 90-day mortality.</p><p><strong>Results: </strong>High AGEF scores correlated with significantly higher mortality (56.1 vs. 19.7%, P < 0.05). AGEF was significantly associated with 90-day mortality [hazard ratio: 1.33, per 1-point increase, 95% confidence interval (95% CI) 1.03-1.70, P < 0.001; hazard ratio: 1.65, per 1 standard deviation increase, 95% CI 1.27-2.14, P < 0.001]. The high AGEF group had a two-fold higher risk of 90-day mortality (hazard ratio: 3.08, 95% CI 1.48-6.41, P < 0.001). Kaplan-Meier curve analysis revealed a higher probability of 90-day death in the group with higher AGEF scores. The restricted cubic spline analysis also suggested a linear relationship between AGEF and 90-day mortality. The area under the receiver-operating characteristic curve for the AGEF was 0.71 (95% CI 0.633-0.787), indicating moderate discrimination ability.</p><p><strong>Conclusion: </strong>AGEF is significantly associated with all-cause 90-day mortality in patients experiencing cardiogenic shock, indicating its potential as a prognostic indicator in this patient population.</p>","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"269-279"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy.","authors":"Angelica Cersosimo, Ludovica Amore, Giuliana Cimino, Gianmarco Arabia, Matteo Pagnesi, Riccardo Maria Inciardi, Marianna Adamo, Marco Metra, Enrico Vizzardi","doi":"10.2459/JCM.0000000000001733","DOIUrl":"10.2459/JCM.0000000000001733","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Dilated cardiomyopathy (DCM) is a common cause of heart failure with reduced ejection fraction (HFrEF) in industrialized countries and a major contributor to morbidity and mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated significant benefits in HFrEF management; however, their impact on endothelial function in this patient population remains less explored. This study aims to evaluate the effects of SGLT2i on endothelial function and echocardiographic parameters in patients with DCM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This observational, longitudinal, monocentric study enrolled patients with DCM and HFrEF. Endothelial function was assessed using peripheral arterial tonometry (EndoPAT) at baseline, 6 months, and 12 months following the initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2i). The enrollment period spanned from November 2021 to November 2022. The primary endpoint was the change in reactive hyperemia index (RHI) over time. In addition, a subgroup analysis was conducted to compare the effects of different SGLT2i agents (empagliflozin vs. dapagliflozin) and DCM etiology (ischemic vs. idiopathic) on endothelial function.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 102 patients were included, predominantly male (72%), with a median age of 75 years and an average baseline left ventricular ejection fraction (LVEF) of 32.9 ± 7.9%. NYHA class II/III was observed in 76% of participants, and ischemic etiology accounted for 53% of DCM cases. The baseline RHI value was 1.15 ± 0.34. At 6 months, it significantly increased to 1.40 ± 0.34 (P &lt; 0.0001), reflecting an absolute change of 0.25 ± 0.03 (ΔRHI baseline - 6 months). Between 6 and 12 months, the RHI showed a further significant increase to 1.69 ± 0.36 (P &lt; 0.0001), with an additional change of 0.29 ± 0.03 (ΔRHI 6 - 12 months). The overall change in RHI from baseline to 12 months (ΔRHI baseline - 12 months) was 0.54 ± 0.04 (P &lt; 0.0001). No significant differences in RHI were observed between patients treated with dapagliflozin and those receiving empagliflozin (P = 0.589), nor between different DCM etiologies (ischemic vs. idiopathic, P = 0.463). The enhancement in RHI was associated with a reduction in the incidence of hospitalization for heart failure (AUC 0.783, P &lt; 0.001). Progressive improvement in left ventricular function was observed through echocardiographic parameters. Although EDV and ESV showed a decreasing trend (EDV: 176.2 ± 64.9 to 167.6 ± 31.1 ml, P = 0.335; ESV: 124.5 ± 52.7 to 116.8 ± 24.6 ml, P = 0.606), these changes were not statistically significant. LVEF improved significantly from 32.9 ± 7.9% at baseline to 36.8 ± 5.5% at 6 months and 37.1 ± 4.9% at 12 months (P &lt; 0.001). The E/A ratio declined from 1.5 ± 0.5 to 1.1 ± 0.3 (P = 0.023) and the E/E' ratio decreased from 18.1 ± 5.1 to 11.1 ± 2.8 (P = 0.027).Left atrial volume significantly decreased from 108 to 100 ml (P = 0.041), and pulmonary artery systo","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"284-296"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A strange hole between the two sides of the heart.","authors":"Massimo Mapelli, Giulia Grilli, Manuela Muratori","doi":"10.2459/JCM.0000000000001730","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001730","url":null,"abstract":"","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"320-321"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial fibrillation ablation versus medical therapy in arrhythmia-induced cardiomyopathy: a propensity score analysis.","authors":"Sofia Capocci, Luca Tomasi, Bruna Bolzan, Anna Piccoli, Elena Franchi, Daniele Battistella, Flavio Luciano Ribichini, Giacomo Mugnai","doi":"10.2459/JCM.0000000000001736","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001736","url":null,"abstract":"<p><strong>Introduction: </strong>Arrhythmia-induced cardiomyopathy (AIC) due to atrial fibrillation is probably related to high ventricular rates and irregular rhythm caused by atrial fibrillation. We sought to investigate the efficacy of pulmonary vein isolation (PVI) using radiofrequency catheter ablation (RFCA) compared to conventional medical therapy in terms of rate of hospitalizations and atrial fibrillation recurrence.</p><p><strong>Methods: </strong>All patients diagnosed with atrial fibrillation associated with heart failure and left ventricular ejection fraction (LVEF) less than 50%, with no other identifiable cause of heart failure aside from the tachyarrhythmia, were included. A 1 : 1 propensity score matching was carried out including age, sex, diabetes, LVEF and BMI in the logistic regression model. The primary endpoint was to assess recurrences of hospitalizations for heart failure; secondary endpoints included hospitalizations for all causes and recurrence of atrial fibrillation during the follow-up.</p><p><strong>Results: </strong>Seventeen patients who had undergone RFCA were matched and compared with 17 patients under conventional medical therapy. Over a median follow-up of 26 months [interquartile range (IQR) 13.4-32], the RFCA group exhibited a significantly lower rate of heart failure-related hospitalization compared with the control group (23.5 versus 58.8%, P = 0.04). The rates of all-cause hospitalizations and atrial fibrillation recurrence were also significantly lower in the RFCA group. The RFCA group also showed a significant increase in LVEF and a significant reduction in left atrial volume compared with medical therapy alone.</p><p><strong>Conclusion: </strong>In patients with AIC due to atrial fibrillation, catheter ablation seems to favor the reverse remodeling and to be effective in reducing atrial recurrence and the rate of all-cause and heart failure-related hospitalizations.</p>","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"314-319"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OBITUARY OF ELIGIO PICCOLO (1928-2025).","authors":"","doi":"10.2459/JCM.0000000000001745","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001745","url":null,"abstract":"","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"257"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanical external compression devices to manage bleeding during mechanical circulatory support with Impella CP.","authors":"Andrea Mariani, Domenico Simone Castiello, Mario Iannaccone, Giacomo Giovanni Boccuzzi, Raffaele Piccolo, Giovanni Esposito","doi":"10.2459/JCM.0000000000001727","DOIUrl":"10.2459/JCM.0000000000001727","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a significant increase in the use of mechanical circulatory support devices, including the Impella device (Abiomed, Danvers, MA, USA), as hemodynamic support during high-risk percutaneous coronary intervention (PCI) and in acute management of cardiogenic shock.</p><p><strong>Results: </strong>In this case series, we present two patients with non-ST-elevation myocardial infarction complicated by cardiogenic shock treated with Impella CP-protected PCI. After the revascularization, for both patients, a clinically relevant, access-site bleeding occurred, challenging the Impella CP maintenance. However, hemostasis was successfully achieved with a mechanical external compression device, allowing Impella hemodynamic support to continue.</p><p><strong>Major findings: </strong>In this case series we propose a novel and easy approach to manage access-site bleeding while using the Impella catheter.</p>","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"312-313"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined use of cardiac magnetic resonance and optical coherence tomography to unravel a MINOCA presentation.","authors":"Antonino Imbesi, Maria Sara Mauro, Maria Cristina Inserra, Davide Capodanno","doi":"10.2459/JCM.0000000000001743","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001743","url":null,"abstract":"","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"322-323"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factor XI inhibitors: is it time for a paradigm shift in anticoagulation?","authors":"Paolo Ossola, Claudio Ciampi, Andrea Cesari, Luca Villanova, Niccolò Grieco, Giovanna Viola, Alice Sacco, Leonardo De Luca, Fabrizio Oliva","doi":"10.2459/JCM.0000000000001735","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001735","url":null,"abstract":"<p><p>Factor XI (FXI) is one of the components of the coagulation cascade, connecting its intrinsic and common pathway. FXI inhibitors have emerged in these few years as interesting therapeutic drugs, with potential advantages over standard anticoagulants in terms of lowering thrombotic risk and limiting bleeding consequences. Better knowledge of the underlying processes of thrombosis led to the design of several clinical trials based on the inhibition of this factor. The discovery of molecules, antibodies, and antisense oligonucleotides capable of binding to this factor is paving the way for new anticoagulation strategies, which will be analyzed in this review.</p>","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"303-311"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}